Sinovent
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Sinovent - overview
Established
2017
Location
Suzhou, Jiangsu, China
Primary Industry
Biotechnology
About
Founded in 2017 and based in Suzhou, China, Sinovent operates as a biopharmaceuticals firm that offers small molecule drug research and development services. The company has set up branch offices in Boston, Beijing, Shanghai, and Sydney. There are 252 employees in the company. In August 2020, it raised CNY 1 billion in series C funding.
In February 2024, Sinovent raised CNY 700 million in series E funding. Sinovent has developed a pipeline of innovative drugs such as BLI inhibitors, EZH2 inhibitors, hURAT1 inhibitors, and new-generation ADCs, utilizing its own technology platforms of targeted therapies, anti-infectives, and PROTACs. XNW4107 is a β-lactamase broad-spectrum anti-drug-resistant bacterial drug with antimicrobial efficacy against Acinetobacter baumannii (CRAB), Pseudomonas aeruginosa (CRPA), and carbapenem antibiotic-resistant Enterobacteriaceae (CRE). EZH2 inhibitor XNW5004 can be used to treat blood cancer and prostate cancer.
And XNW3009 is a uric acid-lowering drug. The company’s revenue is generated by providing drugs for treating diseases such as tumors, anti-infections and metabolism. The company will continue to improve the technology platforms of targeted therapy, anti-infection and PROTAC, and accelerate the operation of production bases as well as the construction of commercialization teams.
Current Investors
Loyal Valley Capital, Origin VC, Shenzhen Fanyou Venture Investment
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Healthcare IT, Pharmaceutical Research & Development
Website
www.sinovent.com.cn/
Verticals
HealthTech
Total Amount Raised
Subscriber access only
Sinovent - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Buyout | Completed | Sinovent | - |
Displaying 1 - 1 of 1
Sinovent - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| Chief Executive Officer | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.